Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3141133 | 0.89 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL3150459 | 0.87 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL3145570 | 0.86 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL2856925 | 0.83 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MAPTGAAMAPK1 | |
| SCHEMBL2863647 | 0.80 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL3145407 | 0.79 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL3142396 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL8273183 | 0.79 | SIRT2 (0.49) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL2864146 | 0.79 | CCR2 (0.48) | ALDH1A1SMN1; SMN2MAPTCYP1A2GAA | |
| SCHEMBL3144465 | 0.78 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747196-B1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-02-10 | — | — | EP | claimed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | claimed |
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767706-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-1747196-B1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS INC (US) | 2010-02-10 | — | — | EP | disclosed |
| US-20100029652-A1 | Combination Therapy For Treating Hepatitis C Infections | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2091524-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS C INFECTIONS | Achillion Pharmaceuticals, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2008076443-A2 | COMBINATION THERAPY FOR TREATING HEPATITIS C INFECTIONS | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365068-B2 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029652-A1 | Combination Therapy For Treating Hepatitis C Infections | HAVCR2, SLC10A1, CYP7A1 | ALDH1A1 235/4885SMN1; SMN2 2647/4885MAPT 3772/4885 |
| US-20060025416-A1 | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | PIGS, NAT1, AADAC | ALDH1A1 176/4885SMN1; SMN2 3029/4885MAPT 3157/4885 |
| US-20090023730-A1 | SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION | PIGS, NAT1, AADAC | ALDH1A1 176/4885SMN1; SMN2 3029/4885MAPT 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.